Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review.

Open access
Breeksema, Joost J, Kuin, Bouwe W, Kamphuis, Jeanine, van den Brink, Wim, Vermetten, Eric, Schoevers, Robert A · 2022 · Journal of Psychopharmacology

Abstract

Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is important to know the full range of adverse events (AEs) for making balanced treatment decisions. Objective: To systematically review the presence of AEs during and after administration of serotonergic psychedelics and 3,4-methyenedioxymethamphetamine (MDMA) in clinical studies. Methods: We systematically searched PubMed, PsycINFO, Embase, and ClinicalTrials.gov for clinical trials with psychedelics since 2000 describing the results of quantitative and qualitative studies. Results: We included 44 articles (34 quantitative + 10 qualitative), describing treatments with MDMA and serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) in 598 unique patients. In many studies, AEs were not systematically assessed. Despite this limitation, treatments seemed to be overall well tolerated. Nausea, headaches, and anxiety were commonly reported acute AEs across diagnoses and compounds. Late AEs included headaches (psilocybin, MDMA), fatigue, low mood, and anxiety (MDMA). One serious AE occurred during MDMA administration (increase in premature ventricular contractions requiring brief hospitalization); no other AEs required medical intervention. Qualitative studies suggested that psychologically challenging experiences may also be therapeutically beneficial. Except for ayahuasca, a large proportion of patients had prior experience with psychedelic drugs before entering studies. Conclusions: AEs are poorly defined in the context of psychedelic treatments and are probably underreported in the literature due to study design (lack of systematic assessment of AEs) and sample selection. Acute challenging experiences may be therapeutically meaningful, but a better understanding of AEs in the context of psychedelic treatments requires systematic and detailed reporting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811221116926

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Flowchart.
Figure 1. Flowchart.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 116 references

Research works printed but not linked: 6

  1. Kirkpatrick M, De Wit H (2014) The acute effects of MDMA in social contexts. Neuropsychopharmacology 39: S466.
  2. Lindsay B (2022) Health Canada announces review of all MDMA trials as complaint alleges major flaws and safety issues. CBC News. Available at: https://www.cbc.ca/news/canada/british-columbia/health-canada-mdma-trial-complaints-flaws-safety-issues-1.6409849 (accessed 8 April 2022).
  3. Mithoefer MC, Doblin R, Mithoefer A, et al. (2013a) A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder. Santa Cruz, CA: MAPS.
  4. Peryer G Golder S Junqueira D et al. (2021) Chapter 19: Adverse effects. In: Higgins JPT Thomas J Chandler J et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (Updated February 2021). Cochrane. Available at: http://www.training.cochrane.org/handbook (accessed 21 March 2022).
  5. Vizeli P, Holze F, Schmid Y, et al. (2019) At ease-subjective effects of MDMA in placebo-controlled studies with healthy subjects. Psychother Psychosom 88: 133–134.
  6. 10.1038/sj.npp.1395197 · DOI · Paper page

Cited by

See all 178

Metadata

Authors
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A.
Affiliations
  • University Medical Center Groningen (NL)
  • Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands
  • Leiden University Medical Center (NL)
Corresponding author
Breeksema, Joost J
Venue
Journal of Psychopharmacology
Published
2022-08-26
Volume
36
Issue
10
Pages
1100-1117
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W4293194637
Cited by
178
References
116
Citations by year
2026: 29 · 2025: 47 · 2024: 73 · 2023: 29
FWCI
6.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
adverse events, serotonergic psychedelics, MDMA, psilocybin, lysergic acid diethylamide, ayahuasca, psychedelic therapy, adverse event reporting, premature ventricular contractions, tolerability
MeSH terms
Hallucinogens, Headache, Humans, Lysergic Acid Diethylamide, Psilocybin, N-Methyl-3,4-methylenedioxyamphetamine, Banisteriopsis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. https://app.cochat.ai/papers/10.1177/02698811221116926
The paper
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022). Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221116926

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.